Literature DB >> 1695090

Metastatic pheochromocytoma associated with multiple endocrine neoplasia syndrome type II.

A H Chevinsky1, J P Minton, J M Falko.   

Abstract

Pheochromocytoma is a rare adrenal medullary tumor of chromaffin cell origin that presents a syndrome of alpha- and beta-adrenergic receptor stimulation due to secretion of epinephrine and norepinephrine. This tumor occurs sporadically in the population and is also associated with multiple endocrine neoplasia syndrome type II (MEN II). Although malignant pheochromocytoma is associated with sporadic tumors, those associated with familial MEN syndromes are rarely malignant. We report a case of a rare metastatic pheochromocytoma in a patient with MEN IIA. Surgical debulking, which has been shown to benefit many patients with metastatic neuroendocrine tumors, was attempted in this patient. Palliation, with symptom relief, was provided. The options for treatment of metastatic pheochromocytoma are discussed.

Entities:  

Mesh:

Year:  1990        PMID: 1695090     DOI: 10.1001/archsurg.1990.01410190133023

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  3 in total

1.  [Therapy of a malignant sympathetic paraganglioma of the organ of Zuckerkandl--a case report].

Authors:  F Schuppert; G F Scheumann; C Schöber; J Overbeck; T H Schürmeyer; H J Schmoll; H Dralle; A von zur Mühlen
Journal:  Klin Wochenschr       Date:  1991-12-11

Review 2.  Management of medullary thyroid carcinoma and MEN2 syndromes in childhood.

Authors:  Steven G Waguespack; Thereasa A Rich; Nancy D Perrier; Camilo Jimenez; Gilbert J Cote
Journal:  Nat Rev Endocrinol       Date:  2011-08-23       Impact factor: 43.330

3.  Partial versus total adrenalectomy by the posterior retroperitoneoscopic approach: early and long-term results of 325 consecutive procedures in primary adrenal neoplasias.

Authors:  Martin K Walz; Klaus Peitgen; Daniela Diesing; Stephan Petersenn; Onno E Janssen; Thomas Philipp; Klaus A Metz; Klaus Mann; Kurt W Schmid; Hartmut P H Neumann
Journal:  World J Surg       Date:  2004-11-11       Impact factor: 3.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.